Tirzepatide
Also known as: Mounjaro · Zepbound
A first-in-class dual GIP/GLP-1 receptor agonist that has demonstrated the most potent weight loss results of any pharmaceutical agent, averaging 20-26% body weight reduction.
Overview
Tirzepatide is a groundbreaking dual agonist peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual mechanism represents a paradigm shift in metabolic therapy, as it harnesses two complementary incretin pathways simultaneously. In the SURMOUNT clinical trials, tirzepatide at its highest dose (15 mg weekly) produced unprecedented weight loss results — an average of 20.9-26.6% of body weight over 72 weeks, with over one-third of participants losing more than 25% of their body weight. These results surpass those of semaglutide and approach the efficacy of bariatric surgery.
Tirzepatide is FDA-approved both for type 2 diabetes (as Mounjaro) and for chronic weight management (as Zepbound). The GIP receptor activation provides additional benefits beyond GLP-1 alone, including enhanced fat oxidation, improved lipid metabolism, and potentially better preservation of lean mass during weight loss. Real-world data has confirmed its superiority over semaglutide for both weight loss and glycemic control.
Mechanism of Action
Dual agonist of GIP and GLP-1 receptors. GLP-1R activation slows gastric emptying, reduces appetite, and enhances insulin secretion. GIP receptor activation enhances fat oxidation, improves lipid metabolism, and may promote brown adipose tissue thermogenesis. The C20 fatty diacid moiety enables albumin binding for weekly dosing.
Key Benefits
Potential Side Effects
Common Stacks
This peptide is commonly combined with the following compounds for synergistic effects:
Known Interactions
The following interactions have been documented for Tirzepatide. Always consult a healthcare professional before combining compounds.
Contraindicated (2)
Both are GLP-1 receptor agonists. Using together doubles the risk of severe GI side effects (nausea, vomiting, pancreatitis) with no additional benefit.
Both include GLP-1 and GIP agonism. Combining creates excessive receptor stimulation with severe GI side effects and hypoglycemia risk.
Scientific References
Quick Reference
Typical Dose
2.5-15 mg/week (titrated up over 20+ weeks)
Frequency
Once weekly
Route
Subcutaneous injection
Half-Life
~5 days
Cycle Length
Ongoing (chronic therapy)
FDA Status
FDA approved (Mounjaro for T2D; Zepbound for weight management)
Need to calculate dosing?
Use our reconstitution calculator to determine exact syringe measurements.
Open CalculatorThis information is for educational purposes only. Consult a qualified healthcare professional before using any peptide. Dosing information reflects commonly reported protocols and may not be appropriate for everyone.
Related Peptides in Fat Loss & Metabolic
Semaglutide
An FDA-approved GLP-1 receptor agonist that has revolutionized weight management, producing average weight loss of 15-17% of body weight in clinical trials.
Read moreAOD-9604
A modified fragment of human growth hormone (amino acids 176-191) that retains the fat-burning properties of HGH without its growth-promoting or diabetogenic effects.
Read moreMOTS-c
A mitochondrial-derived peptide that acts as an exercise mimetic, improving metabolic homeostasis, insulin sensitivity, and reducing age-related metabolic decline.
Read more